Cancer Letters
Volume 205, Issue 2 , Pages 161-171 , 18 March 2004

Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin α-conjugate

  • Yong Li

      Affiliations

    • Center for Experimental Radiation Oncology, Cancer Care Center, St George Hospital, Gray St, Kogarah 2217, New South Wales, Australia
    • ,
  • Paul J Cozzi

      Affiliations

    • Department of Surgery, St George Hospital, Gray St, Kogarah, UNSW, New South Wales 2217, Australia
    • Department of Medicine, University of New South Wales, Kensington, New South Wales 2052, Australia
    • ,
  • Chang F Qu

      Affiliations

    • Center for Experimental Radiation Oncology, Cancer Care Center, St George Hospital, Gray St, Kogarah 2217, New South Wales, Australia
    • Department of Medicine, University of New South Wales, Kensington, New South Wales 2052, Australia
    • ,
  • David Y Zhang

      Affiliations

    • Center for Experimental Radiation Oncology, Cancer Care Center, St George Hospital, Gray St, Kogarah 2217, New South Wales, Australia
    • ,
  • Syed M Abbas Rizvi

      Affiliations

    • Center for Experimental Radiation Oncology, Cancer Care Center, St George Hospital, Gray St, Kogarah 2217, New South Wales, Australia
    • Department of Medicine, University of New South Wales, Kensington, New South Wales 2052, Australia
    • ,
  • Chand Raja

      Affiliations

    • Center for Experimental Radiation Oncology, Cancer Care Center, St George Hospital, Gray St, Kogarah 2217, New South Wales, Australia
    • ,
  • Barry J Allen

      Affiliations

    • Center for Experimental Radiation Oncology, Cancer Care Center, St George Hospital, Gray St, Kogarah 2217, New South Wales, Australia
    • Department of Medicine, University of New South Wales, Kensington, New South Wales 2052, Australia
    • Corresponding Author InformationCorresponding author. Address: Center for Experimental Radiation Oncology, Cancer Care Center, St George Hospital, Gray St, Kogarah 2217, New South Wales, Australia. Tel.: +61-2-9350-3855; fax: +61-2-9350-2456

Received 28 July 2003 ,Revised 11 October 2003 ,Accepted 25 October 2003.

References 

  1. Klijanienko J, Couturier J, Galut M, El-Naggar AK, Ma-ciorowski Z, Padoy E, et al.  Detection and quantitation by fluorescence in situ hybridization (FISH) and image analysis of HER-2/neu gene amplification in breast cancer fine-needle samples. Cancer. 1999;87:312–318
  2. Wang S, Saboorian MH, Frenkel E, Hynan L, Gokastan ST, Ashfag R. Laboratory assessment of the status of Her-2/neu protein and oncogen in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridization assays. J. Clin. Pathol. 2000;53:374–381
  3. Ross JS, Yang F, Kallakury BV, Sheehan CE, Ambros RA, Muraca PJ. HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary. Am. J. Clin. Pathol. 1999;111:311–316
  4. Shackney SE, Smith CA, Pollice A, Levitt M, Magovern JA, Wiechmann RJ, et al.  Genetic evolutionary staging of early non-small cell lung cancer: the p53 HER-2/NEU ras sequence. J. Thorac. Cardiovasc. Surg. 1999;118:259–267
  5. Cox G, Vyberg M, Melgaard B, Askaa J, Oster A, O'Byrne KJ. Herceptest: Her2 expression and gene amplification in non-small cell lung cancer. Int. J. Cancer. 2001;92:480–483
  6. Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, et al.  Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br. J. Cancer. 2002;86:1449–1456
  7. Ross JS, Sheehan CE, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman RP, et al.  Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer. 1997;79:2162–2170
  8. Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A, Greene MI. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene. 1994;9:2109–2123
  9. Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, et al.  Epidermal growth factor receptor and HER-2 neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin. Cancer Res. 2001;7:1850–1855
  10. Mellon K, Thompson S, Charlton RG, Marsh C, Robinson M, Lane DP, et al.  P53, c-erbB-2 and the epidermal growth-factor receptor in the begin and malignant prostate. J. Urol. 1992;147:496–499
  11. Zhau HE, Wan DS, Zhou J, Miller GJ, von Eschenbach AC. Expression of c-erbB-2/neu proto-oncogene in human prostate cancer tissues and cell lines. Mol. Carcinogen. 1992;5:320–327
  12. Strohmeyer TG, Slamon DJ. Proto-oncogenes and tumor suppressor genes in human urological malignancies. J. Urol. 1994;151:1479–1497
  13. Lara PN, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Kauderer C, et al.  Her-2/neu is overexpressed infrequently in patients with prostate carcinoma. Cancer. 2002;94:2584–2589
  14. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase [see comments]. Nat. Med. 1999;5:280–285
  15. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. USA. 1999;96:5458–5463
  16. Arai Y, Yoshiki T, Yoshida O. c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer. Prostate. 1997;30:195–201
  17. Morote J, Torres ID, Caceres C, Vallejo C, Schwartzjr S, Reventos J. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer. Int. J. Cancer. 1999;84:421–425
  18. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, et al.  Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl. Cancer Inst. 2000;92:1918–1925
  19. Meng TC, Lee MS, Lin MF. Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. Oncogene. 2000;19:2664–2677
  20. Osman I, Scher HI, Drobnjak M, Verbal D, Morris M, Agus D, et al.  HER-2/neu (p 185neu) protein expression in the natural or treated history of prostate cancer. Clin. Cancer Res. 2001;7:2643–2647
  21. Agus AD, Scher HI, Higgins B, Fox WD, Heller G, Fazzari M, et al.  Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models. Cancer Res. 1999;59:4761–4764
  22. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. 1990;5:953–962
  23. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA. 1992;89:4285–4289
  24. Colomer R, Shamon LA, Tsai MS, Lupu R. Herceptin: from the bench to the clinic. Cancer Investig. 2001;19:49–56
  25. Baselga J, Tripathy D, Mendelsohn J, Baaghman S, Benz CC, Dantis L, et al.  Phase II study of weekly intravenous recombinant humanised anti-p185 (HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 1996;14:737–744
  26. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al.  Multinational study of the efficacy and safety of humanised anti-HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 1999;17:2639–2648
  27. Allen BJ, Blagojevic N. Alpha and beta emitting radiolanthanides in targeted cancer therapy. Nucl. Med. Commun. 1997;17:40–47
  28. Rizvi SMA, Sarkar S, Goozee G, Allen BJ. Radioimmunocojugates for targeted alpha therapy of malignant melanoma. Melanoma Res. 2000;10:281–290
  29. Li Y, Rizvi SMA, Ranson M, Allen BJ. 213Bi-PAI2 conjugated selectively induces apoptosis in PC3 metastatic cancer cell line and shows anti-cancer activity in a xenograft animal model. Br. J. Cancer. 2002;86:1197–1230
  30. Li Y, Tian Z, Rizvi SMA, Bander NH, Allen BJ. In vitro and prelinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis. 2002;5:36–46
  31. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell. Biol. 1992;119:493–501
  32. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al.  Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl J. Med. 2001;344:783–792
  33. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science. 1987;235:177–182
  34. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keiet DE, et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712
  35. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl. Acad. Sci. USA. 1987;84:7159–7163
  36. Di Fiore PP, Pierce JH, Krasu MH, Segatto O, King CR, Aaronson SA. erbB-2 Is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 1987;237:178–182
  37. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the human neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA. 1992;89:10578–10582
  38. Chazin VR, Kaleko M, Miller AD, Slamon DJ. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor. Oncogene. 1992;7:1859–1866
  39. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, et al.  HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 1995;10:2435–2446
  40. Zhang M, Yao Z, Garmestani K, Axworthy DB, Zhang Z, Mallett RW, et al.  Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the α-emitting radionuclide, bismuth 213. Blood. 2002;100:208–216
  41. Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi C, et al.  Targeted α particle immunotherapy for myeloid leukemia. Blood. 2002;100:1233–1239
  42. Kennel SJ, Boll R, Stabin M, Schuller HM, Mirzadeh S. Radioimmunotherapy of micrometastases in lung with vascular targeted 213Bi. Br. J. Cancer. 1999;80:175–184
  43. McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, et al.  An α-particle emitting antibody ([213Bi]j591) for radioimmunotherapy of prostate cancer. Cancer Res. 2000;60:6059–6100
  44. Raju MR, Eisen Y, Carpenter S, Inkret WC. Radiobiology of alpha particles, III: cell inactivation by alpha-particle traversal of the cell nucleus. Radiat. Res. 1991;128:204–209
  45. Chang CH, Sharkey RM, Rossi EA, Karacay H, McBride W, Hansen HJ, et al.  Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol. Cancer. Ther. 2002;1:553–563
  46. Wang L, Liu B, Schmidt M, Lu Y, Wells W, Fan Z. Antitumor effect of an HER-2-specific antibody-toxin fusion protein on human prostate cancer cells. Prostate. 2001;47:21–28
  47. Nikula TK, McDevitt MR, Finn RD, Wu C, Kozak RW, Garmestani K, et al.  Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J. Nucl. Med. 1999;40:166–176
  48. Macklis RM, Lin JY, Beresford B, Atcher RW, Hines JJ, Humm JL. Cellular kinetics, dosimetry, and radiobiology of α-particle radioimmunotherapy: induction of apoptosis. Radiat. Res. 1992;130:220–226

PII: S0304-3835(03)00821-8

doi: 10.1016/j.canlet.2003.10.035

Cancer Letters
Volume 205, Issue 2 , Pages 161-171 , 18 March 2004

Article Tools

* Image Usage & Resolution